Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483327 · ClinicalTrials.gov registry record · Phase 2
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00483327 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 31 participants.
The verdict
NCT00483327, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial Hyperplasia or well to moderately differentiated endometrial carcinoma.
Interventions
- DRUG Megestrol Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483327
The ClinicalTrials.gov registry entry for NCT00483327 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Megestrol Acetate is the first listed.
NCT00483327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483327 about?
NCT00483327 is a clinical study titled "Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate". The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial Hyperplasia or well to moderately differentiated endometrial carcinoma.
What is the current status of trial NCT00483327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2007-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00483327?
The interventions under investigation include: Megestrol Acetate (DRUG).
Who is sponsoring clinical trial NCT00483327?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.